Welcome to the PREPARE Questionnaire!
This questionnaire has been developed by a team of researchers from the Department of Psychiatry and Psychotherapy at the Charité Universitätsmedizin in Berlin and the Central Institute of Mental Health, Mannheim, Germany. With our growing experience in clinical trials using psychedelic-assisted therapy, we observe important therapeutic potential. However, many open questions remain, particularly regarding factors that may predict therapeutic outcomes.
Are there demographic or clinical parameters that predict favourable therapeutic outcomes, like response or remission? Or perhaps others that predict less favourable outcomes, like strong fear reactions, sleep disturbances, or impaired psychosocial functioning?
To shed some light on these questions, we want to anonymously collect valuable observations and experiences from clinicians. Our questionnaire is aimed at practitioners (psychiatrists, clinical psychologists, psychotherapists, or other mental health professionals) either providing psychedelic-assisted therapy directly or having worked with patients/clients in preparation and/or integration of psychedelic experiences (i.e., integration therapists). We welcome participation from individuals conducting psychedelic-assisted therapy in all contexts: legal clinical practice, clinical trials, retreat centres, and 'underground' therapy. We are interested in psychedelic-assisted therapy with classic psychedelics (psilocybin, LSD, DMT, ayahuasca, mescaline, peyote) as well as MDMA, ketamine and ibogaine.
By sharing your precious knowledge as experts in this innovative therapy, you can contribute to the development of better, safer and more efficacious trial protocols.
The total time required to complete the questionnaire is approximately 20 minutes.
It is best use a laptop or computer to ensure all scales are displayed correctly. If you are using mobile devices, please use landscape mode.
We sincerely thank you for your participation in the study,
PD Dr. med. Felix Betzler, Dr. med. Michael Koslowski, Grace Viljoen (MSc) and the entire research team